Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT02179671
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
Combination of Chemotherapy and Gefitinib as First-line Treatment
- Conditions
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Baohui Han
- Target Recruit Count
- 121
- Registration Number
- NCT02148380
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 56
- Registration Number
- NCT02088112
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 27
- Registration Number
- NCT02040064
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 267
- Registration Number
- NCT02039674
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 250
- Registration Number
- NCT02031601
- Locations
- 🇨🇳
Yu Li, Jinan, Shandong, China
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 88
- Registration Number
- NCT01982955
- Locations
- 🇨🇳
Jilin University, Changchun, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, China
Third-line Treatment of Gefitinib in NSCLC Patients
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 46
- Registration Number
- NCT01933347
- Locations
- 🇨🇳
Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT01833572
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 95
- Registration Number
- NCT01783834
- Locations
- 🇰🇷
Gachon university Gil Medical Center, Incheon, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.